JP2024512024A5 - - Google Patents

Info

Publication number
JP2024512024A5
JP2024512024A5 JP2023558377A JP2023558377A JP2024512024A5 JP 2024512024 A5 JP2024512024 A5 JP 2024512024A5 JP 2023558377 A JP2023558377 A JP 2023558377A JP 2023558377 A JP2023558377 A JP 2023558377A JP 2024512024 A5 JP2024512024 A5 JP 2024512024A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutically acceptable
stereoisomer
prodrug
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/021573 external-priority patent/WO2022204299A1/en
Publication of JP2024512024A publication Critical patent/JP2024512024A/ja
Publication of JP2024512024A5 publication Critical patent/JP2024512024A5/ja
Pending legal-status Critical Current

Links

JP2023558377A 2021-03-23 2022-03-23 Lrrk2キナーゼ阻害剤として有用なピリミジン誘導体 Pending JP2024512024A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163164804P 2021-03-23 2021-03-23
US63/164,804 2021-03-23
PCT/US2022/021573 WO2022204299A1 (en) 2021-03-23 2022-03-23 Pyrimidine derivatives useful as lrrk2 kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2024512024A JP2024512024A (ja) 2024-03-18
JP2024512024A5 true JP2024512024A5 (cg-RX-API-DMAC10.html) 2025-03-18

Family

ID=81328290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558377A Pending JP2024512024A (ja) 2021-03-23 2022-03-23 Lrrk2キナーゼ阻害剤として有用なピリミジン誘導体

Country Status (12)

Country Link
US (4) US11578061B2 (cg-RX-API-DMAC10.html)
EP (1) EP4313955A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024512024A (cg-RX-API-DMAC10.html)
KR (1) KR20230170684A (cg-RX-API-DMAC10.html)
CN (1) CN117355507A (cg-RX-API-DMAC10.html)
AU (1) AU2022246081A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023019388A2 (cg-RX-API-DMAC10.html)
CA (1) CA3214360A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023012903A2 (cg-RX-API-DMAC10.html)
IL (1) IL306008A (cg-RX-API-DMAC10.html)
MX (1) MX2023011027A (cg-RX-API-DMAC10.html)
WO (1) WO2022204299A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022246081A1 (en) * 2021-03-23 2023-10-12 Halia Therapeutics, Inc. Pyrimidine derivatives useful as lrrk2 kinase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AU2010331927B2 (en) 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
EP2512246B1 (en) 2009-12-17 2015-09-30 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
KR101566091B1 (ko) * 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
ES2665421T3 (es) 2013-06-04 2018-04-25 Acturum Real Estate Ab Compuestos de pirimidina y su uso como moduladores de la gamma secretasa
RU2016134751A (ru) * 2014-01-29 2018-03-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
US9879008B2 (en) 2014-04-14 2018-01-30 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
US11214565B2 (en) * 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
US11174248B2 (en) 2017-10-11 2021-11-16 Merck Sharp & Dohme Corp. Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
CA3085561A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
CN110872277B (zh) 2019-11-14 2021-06-04 浙江大学 N-取代芳环-2-氨基嘧啶类化合物及用途
AU2022246081A1 (en) * 2021-03-23 2023-10-12 Halia Therapeutics, Inc. Pyrimidine derivatives useful as lrrk2 kinase inhibitors

Similar Documents

Publication Publication Date Title
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
JP2021535207A5 (cg-RX-API-DMAC10.html)
JP2019522055A5 (cg-RX-API-DMAC10.html)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2019518766A5 (cg-RX-API-DMAC10.html)
MA27390A1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
JP2016513696A5 (cg-RX-API-DMAC10.html)
JP2024513227A5 (cg-RX-API-DMAC10.html)
JP2019529460A5 (cg-RX-API-DMAC10.html)
JP2013542267A5 (cg-RX-API-DMAC10.html)
CA3246041A1 (en) Tetracyclic compound and its use
CN111511745A (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
JPH07502022A (ja) トリアゾール抗真菌剤
CA3088000A1 (en) Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof
HRP20181027T1 (hr) Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a
JP2007505044A5 (cg-RX-API-DMAC10.html)
JP2015502371A5 (cg-RX-API-DMAC10.html)
RU2007116987A (ru) Новые соединения
RU2020124097A (ru) НИЗКОМОЛЕКУЛЯРНЫЕ МОДУЛЯТОРЫ ДОМЕНА BTB Keap1
WO2017187343A2 (en) Nanoemulsions and methods for cancer therapy
RU2008131311A (ru) Производные тритерпенхинона и тритерпенфенола и их применение для лечения опухолей и паразитарных заболеваний
RU2016133213A (ru) Новые функционализированные 1,3-бензолдиолы и способ их применения для лечения печеночной энцефалопатии
JP2022526015A5 (cg-RX-API-DMAC10.html)
JP2019522048A5 (cg-RX-API-DMAC10.html)